Log in to save to my catalogue

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5024539

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

About this item

Full title

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2015-11, Vol.373 (19), p.1814-1823

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In a phase 3 clinical trial involving previously treated patients with advanced renal-cell carcinoma, progression-free survival was significantly longer with the VEGF receptor inhibitor cabozantinib than with everolimus (7.4 months vs. 3.8 months).
Renal-cell carcinoma is the most common form of kidney cancer, with more than 330,000 cases diagno...

Alternative Titles

Full title

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5024539

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5024539

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1510016

How to access this item